PRP vs. Cortisone for Joint and Tendon Pain: What the Evidence Actually Shows

Cortisone injections are fast and familiar, but the long-term picture is more complicated than most patients are told. What cortisone does, where PRP outperforms it, and how to think about the choice.

Cortisone injections are one of the most commonly performed procedures in musculoskeletal medicine — fast, familiar, and often the first injection offered for joint or tendon pain. But the evidence behind cortisone is more complicated than most patients are told, and understanding the difference between what cortisone does versus what PRP does can meaningfully change how you think about your options.

What cortisone actually does

Corticosteroid injections — commonly called cortisone shots — work by suppressing inflammation at the injection site. That is both their strength and their limitation. Inflammation suppression reduces pain and swelling, often quickly. Many patients feel meaningful relief within days, which is why cortisone has remained standard practice for decades.

The problem is that inflammation is part of the healing process. In conditions involving tendon degeneration or cartilage breakdown, the underlying tissue is already in a poor state of repair — and suppressing the inflammatory response does not address the structural problem. It quiets symptoms while the tissue continues to deteriorate. This is why cortisone relief tends to be temporary and why some patients find each subsequent injection works a little less well than the last.

Beyond diminishing returns, a growing body of research has raised specific concerns about repeated corticosteroid use. For tendons in particular, multiple randomized controlled trials have documented worse long-term outcomes with cortisone than with physical therapy alone or with PRP. The same pattern has emerged in several large knee osteoarthritis trials, where regular cortisone injections were associated with accelerated cartilage loss on imaging.

What PRP does differently

Platelet-rich plasma is prepared from the patient's own blood. A blood draw is processed in a centrifuge to concentrate the platelets, which are then injected directly into the affected tissue. Platelets carry a high concentration of growth factors — proteins that signal the body to initiate and sustain a healing response. Rather than suppressing inflammation, PRP aims to direct the tissue toward repair.

This distinction matters most in two situations: when the underlying problem is degenerative rather than purely inflammatory (as in knee osteoarthritis or tendinopathy), and when the goal is durable improvement rather than temporary relief. PRP is not a faster cortisone. It is a different category of treatment aimed at a different biological target.

What the head-to-head evidence shows

There is now a substantial body of randomized controlled trials directly comparing PRP to corticosteroid for the most common conditions. The pattern across conditions is consistent enough to be worth summarizing.

Knee osteoarthritis

This is the most studied comparison. Multiple meta-analyses of randomized trials have found PRP produces significantly better pain and function outcomes than corticosteroid at 6 and 12 months. Short-term (4–6 week) results are often similar — both reduce pain — but the difference in durability is substantial. A 2021 network meta-analysis in the British Journal of Sports Medicine found PRP ranked highest among injections into the knee joint at 12 months, with corticosteroid falling below placebo at the same time point.

Tennis elbow (lateral epicondylitis)

This is another condition where the head-to-head data consistently favors PRP at long-term follow-up. Cortisone reliably wins in the first 4–8 weeks — patients feel better faster. But at 6 months and beyond, multiple RCTs show PRP producing meaningfully better outcomes, with some trials showing cortisone patients performing no better than placebo by the 1-year mark.

Frozen shoulder (adhesive capsulitis)

A 2025 meta-analysis of 7 RCTs found PRP and corticosteroid comparable at one month, with PRP producing significantly better results on pain, range of motion, and functional scores at 3 and 6 months. This is a condition where short-term cortisone relief is real — but patients treated with PRP continue to improve while those treated with cortisone plateau.

Rotator cuff tendinopathy

The evidence here is more mixed, partly because rotator cuff studies often combine different types of pathology. For chronic tendinopathy specifically (as opposed to acute bursitis), PRP has shown favorable results in several trials. For acute flares or bursitis, corticosteroid is still a reasonable short-term option in some cases.

When cortisone still makes sense

Cortisone is not always the wrong choice. There are situations where suppressing inflammation quickly is the right priority — before a significant life event, to enable participation in a rehabilitation program, or when acute bursitis is the primary problem rather than tendon degeneration. The issue is not that cortisone is without value. The issue is that it is often offered as a default when the clinical picture calls for something else.

Repeated cortisone injections into the same tendon or joint — without a clear plan and without reassessment — is where the long-term risk accumulates. Most guidelines now recommend limiting corticosteroid injections in tendons, and increasingly in joints, for exactly this reason.

How to think about the choice

A few questions are worth asking before any injection:

• Is the primary problem inflammatory (acute flare, bursitis) or degenerative (tendinopathy, osteoarthritis)?
• Is the goal short-term relief — for example, to get through a specific event or to enable rehab — or is it durable long-term improvement?
• Have you already had cortisone injections at this site? How many, and with what results over time?
• Has the underlying tissue been assessed with imaging, or is the diagnosis assumed from symptoms alone?

These questions often reframe a decision that was never really examined. For many chronic tendon and joint conditions, PRP has better long-term evidence — and cortisone, while faster in the short term, is not a treatment for the underlying problem.

The bottom line

Cortisone injections are fast and effective at reducing acute inflammation. For chronic tendon degeneration and joint osteoarthritis, the evidence increasingly favors PRP for patients who want durable improvement rather than temporary relief. The best approach depends on an accurate diagnosis, a realistic understanding of what each treatment targets, and a clear-eyed look at your goals.